Clearmind Medicine Inc. Stock price




Biotechnology & Medical Research

End-of-day quote Canadian Securities Exchange 06:00:00 2023-12-03 pm EST Intraday chart for Clearmind Medicine Inc. 5-day change 1st Jan Change
5.17 CAD -8.66% +23.10% -96.12%
Sales 2022 * - Sales 2023 * - Capitalization 10.95M 14.83M
Net income 2022 -9M -12.19M Net income 2023 * - EV / Sales 2022
Net cash position 2022 388K 525K Net cash position 2023 * - 0 EV / Sales 2023 * -
P/E ratio 2022
P/E ratio 2023 *
Employees -
Yield 2022
Yield 2023 *
Free-Float 90.66%
More Fundamentals * Assessed data
Dynamic Chart
Clearmind Medicine's Novel Obesity Drug Shows Positive Results in Pre-Clinical Trial MT
Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial CI
Clearmind Medicine Reports Positive Results From Weight Loss, Metabolic Disorder Program with Psychedelic-based Treatment MT
Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based Treatment CI
Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities CI
Clearmind Medicine Inc. announced that it expects to receive $2.25 million in funding CI
Clearmind Medicine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate Cmnd-100 in Patients with Alcohol Use Disorder CI
Clearmind Medicine Announces Collaboration with Cts Ltd CI
Clearmind Medicine Inc. Files Patent Application with Uspto for the Treatment of Dyskinesia; Further Strengthens Its Already Robust Ip Portfolio CI
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S CI
Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board CI
Certain Restricted Stock Units of Clearmind Medicine Inc. are subject to a Lock-Up Agreement Ending on 3-JUL-2023. CI
Certain Common Shares of Clearmind Medicine Inc. are subject to a Lock-Up Agreement Ending on 3-JUL-2023. CI
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome CI
More news
1 day-8.66%
1 week+23.10%
Current month+3.40%
1 month-9.30%
3 months-71.28%
6 months-76.39%
Current year-96.12%
More quotes
1 week
Extreme 3.61
1 month
Extreme 3.61
Current year
Extreme 3.61
1 year
Extreme 3.61
3 years
Extreme 3.61
5 years
Extreme 3.61
10 years
Extreme 3.61
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 2021
Director of Finance/CFO 71 2019
Corporate Officer/Principal - 2021
Members of the board TitleAgeSince
Director of Finance/CFO 71 2019
Chief Executive Officer 53 2021
Chairman 61 2019
More insiders
Date Price Change Volume
23-12-04 5.17 -8.66% 7,724
23-12-01 5.66 +13.20% 31,301
23-11-30 5 +20.48% 15,690
23-11-29 4.15 -6.74% 5,021
23-11-28 4.45 +5.95% 9,788

End-of-day quote Canadian Securities Exchange, December 03, 2023

More quotes
Clearmind Medicine Inc. is a Canada-based psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company’s intellectual portfolio consists of fourteen patent families. The Company's portfolio consists of patent families, such as alcoholic beverage substitute and binge behaviour regulators.
More about the company
  1. Stock
  2. Equities
  3. Stock Clearmind Medicine Inc. - Canadian Securities Exchange
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments